Factors impacting on sexual function among men on active surveillance for prostate cancer.

Journal: The Prostate

Volume: 83

Issue: 7

Year of Publication: 2023

Affiliated Institutions:  Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, Adelaide, Australia. South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, Australia. Health Policy Centre, South Australian Health and Medical Research Institute, Adelaide, Australia. Flinders Medical Centre, Bedford Park, Australia. Urology Unit, Southern Adelaide Local Health Network, Adelaide, Australia.

Abstract summary 

Active surveillance (AS) aims to reduce overtreatment and minimize the negative side effects of radical therapies (i.e., prostatectomy or radiotherapy) while preserving quality of life. However, a substantial proportion of men can experience a decline in sexual function during AS follow-up. The aim of this study was to identify predictors of declining sexual function among men on AS.Men enrolled from 2008 to 2018 in the South Australian Prostate Cancer Clinical Outcomes Collaborative registry-a prospective clinical registry-were studied. Sexual function outcomes were measured using expanded prostate cancer index composite (EPIC-26) at baseline and 12-months postdiagnosis. Multivariable regression models adjusted for baseline score and other sociodemographic and clinical factors were applied to identify predictors of sexual function score at 12-months.A total of 554 men were included. Variables that showed significant association with decline in sexual function score at 12-months were: having two or more biopsies after diagnosis (mean change score (MCS): -16.3, p < 0.001) compared with no biopsy, higher number of positive biopsy cores (MCS: -1.6, p = 0.004), being in older age category (above 70 vs. below 60: MCS: -16.7, p < 0.001; 65-70 vs. below 60: MCS: -9.7, p = 0.024), having had depression (MCS: -9.0, p = 0.020), and impaired physical function (MCS: -10.0, p = 0.031). Greater socioeconomic advantage (highest vs. lowest quintile: MCS: 15.7, p = 0.022) and year of diagnosis (MCS: 2.6 for every year, p < 0.001) were positively associated with 12-months sexual function score. Neither biopsy type, biopsy timing nor PSA velocity were associated with declines in sexual function.Our findings suggest that multiple factors affected sexual function during AS. Interventions toward reducing the number of biopsies through less invasive monitory approaches, screening for physical and mental well-being, and targeted emotional support and counseling services may be helpful for men on AS.

Authors & Co-authors:  Tiruye Tenaw T O'Callaghan Michael M Ettridge Kerry K Jay Alex A Santoro Kerry K Moretti Kim K Beckmann Kerri K

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Papa N, O'Callaghan M, James E, Millar J. Prostate cancer in Australian and New Zealand men: patterns of care within PCOR-ANZ 2015-2018. 2021.
Authors :  7
Identifiers
Doi : 10.1002/pros.24502
SSN : 1097-0045
Study Population
Men
Mesh Terms
Male
Other Terms
Australia;active surveillance;erectile dysfunction;prostate cancer;quality of life;sexual function
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
United States